NCT00264186View on ClinicalTrials.gov

Recombinant Human Superoxide Dismutase (rhSOD) and Vascular Reactivity

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 30, 2005

Conditions
Inflammation
Interventions
DRUG

LPS 2 ng/kg intravenous (IV) bolus

DRUG

rhSOD 82,000 IU (8.2 mg)/min intraarterially

DRUG

Norepinephrine 60, 120, 240 pmol/min intraarterially over 5 min/dose level (two times; pre-dose and +3.5 hrs)

DRUG

Acetylcholine 6.25, 12.5, 25 nmol/min intraarterially over 3 min/dose level (two times; pre-dose and +3.5 hrs)

DRUG

Glyceroltrinitrate (nitroglycerine) 4, 8, 16 nmol/min over 3 min/dose level (two times; pre-dose and +3.5 hrs)

Trial Locations (1)

1090

Medical University of Vienna - General Hospital of the City of Vienna AKH, Vienna

All Listed Sponsors
collaborator

Polymun Scientific, Vienna, Austria

UNKNOWN

lead

Medical University of Vienna

OTHER

NCT00264186 - Recombinant Human Superoxide Dismutase (rhSOD) and Vascular Reactivity | Biotech Hunter | Biotech Hunter